IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Innate Pharma SA
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026
$1.46+0.03 (+2.10%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2016 to 2025
Operating margin
-599.8%−601.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -55.2% | -46.2% | -33.6% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | – | 3.81 | 1.27 | |
| Interest coverage | – | 0.2× | -17.3× | |
| Capex to revenue | – | 1.3% | 1.6% | |
| Diluted shares | – | 79M | 90M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Innate Pharma generated €169.82M from operations and spent €2.35M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
€169.82M
Used
€2.35M
Capital expenditure€2.35M100%Dividends€00%Share buybacks€00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 4 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-€52.76M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-€52.76M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.60 → 1.27
- No dilutionShare count did not rise81M → 90M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.11 → 0.08